Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026

Sagimet Biosciences Inc.

Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.
Phase 3 U.S. trial of denifanstat in moderate-to-severe acne planned for H2 2026, pending IND clearance.
MASH development paused until non-dilutive funding secured; combination program with resmetirom ready for Phase 2.
New CMO Andreas Grauer appointed; Phase 1 of TVB-3567 ongoing, Phase 2 acne trial targeted for H2 2026.
Positive Phase 3 acne safety results from partner Ascletis in China reported Jan 2026 (n=240).

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sagimet Biosciences Inc. reported preliminary financial results for the Company’s fiscal quarter ended March 31, 2026.

Period: the Company’s fiscal quarter ended March 31, 2026
Result: preliminary results

Exact text from the filing

Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-048971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.